1. Home
  2. DTIL vs BDSX Comparison

DTIL vs BDSX Comparison

Compare DTIL & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Precision BioSciences Inc.

DTIL

Precision BioSciences Inc.

HOLD

Current Price

$5.02

Market Cap

123.0M

Sector

Health Care

ML Signal

HOLD

Logo Biodesix Inc.

BDSX

Biodesix Inc.

HOLD

Current Price

$7.79

Market Cap

53.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DTIL
BDSX
Founded
2006
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Precision Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
123.0M
53.0M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
DTIL
BDSX
Price
$5.02
$7.79
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
5
Target Price
$47.00
$32.50
AVG Volume (30 Days)
253.4K
62.9K
Earning Date
11-03-2025
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$698,000.00
$80,173,000.00
Revenue This Year
N/A
$20.75
Revenue Next Year
$34.30
$25.05
P/E Ratio
N/A
N/A
Revenue Growth
N/A
22.29
52 Week Low
$3.61
$3.44
52 Week High
$8.82
$32.20

Technical Indicators

Market Signals
Indicator
DTIL
BDSX
Relative Strength Index (RSI) 40.77 51.69
Support Level $4.70 $7.68
Resistance Level $5.54 $8.17
Average True Range (ATR) 0.40 0.66
MACD -0.01 0.02
Stochastic Oscillator 28.71 55.68

Price Performance

Historical Comparison
DTIL
BDSX

About DTIL Precision BioSciences Inc.

Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

Share on Social Networks: